#Hong Kong #Breast Cancer #Akeso #HER3 ADC

Akeso's Advancement in Breast Cancer Treatment through HER3 ADC

In a significant development in the fight against breast cancer, Akeso, Inc. has announced that the first patient has been enrolled in their Phase Ib/II clinical study (AK138D1-202). This study evaluates AK138D1, a next-generation antibody-drug conjugate (ADC) designed to target HER3, in combination with ivonescimab. This innovative approach holds promise for treating advanced breast cancer, particularly addressing two of the most prevalent and challenging subtypes.

HER3 is widely expressed in various solid tumors, marking it as a critical target for therapeutic development. These types of tumors include breast, ovarian, colon, and pancreatic cancers, impacting millions of patients worldwide. Traditional HER3-targeted ADCs have shown potential but are often limited by severe side effects. In contrast, AK138D1 is engineered with a novel design aimed at minimizing toxicities while maximizing therapeutic effects, presenting a balanced solution to this pressing healthcare challenge.

The Innovative Design of AK138D1

AK138D1 stands apart thanks to its in-house development and unique characteristics. Unlike previous HER3-targeting therapies, this ADC is designed to limit uptake in normal tissues, thereby reducing unwanted side effects. One of its key features is its ability to avoid the clustering of ADC molecules at the tumor's surface, allowing for more effective penetration and distribution throughout the tumor. This capability helps to overcome the so-called 'binding site barrier,' which has hindered the efficiency of prior approaches.

Early clinical trials in Australia and China have provided promising data, revealing robust anti-tumor activity in breast cancer and an excellent safety profile. Notably, the drug has exhibited low hematologic toxicity and no cases of interstitial lung disease (ILD), thus establishing a solid foundation for its future application in various therapeutic regimens.

Targeting Major Breast Cancer Subtypes

The Phase Ib/II study primarily focuses on two significant breast cancer subtypes: hormone receptor-positive, HER2-negative (HR+/HER2-) and triple-negative breast cancer (TNBC). These subtypes represent approximately 65% and 10-20% of breast cancer cases respectively. The trial is set to recruit patients across several treatment lines, from those newly diagnosed to those with extensive prior treatments. These efforts are timely, as breast cancer remains the most diagnosed cancer among women globally, with around 2.3 million new cases each year.

Despite advancements in treatment, substantial unmet needs still exist, especially in HR+/HER2- and TNBC patients. This study's focus ensures that it addresses these critical gaps in therapeutic care, potentially offering new hope to those battling advanced disease.

Promising Early Results and Future Directions

AK138D1's early studies have already indicated a meaningful effectiveness along with a commendable safety profile in the context of breast cancer treatment. Meanwhile, a Phase III trial involving ivonescimab is also underway, aiming to fortify the therapeutic landscape for first-line TNBC treatment. Together, the combination of AK138D1 and ivonescimab is set to pioneer a 'IO2.0 + ADC2.0' therapeutic strategy, designed to elevate treatment possibilities for those suffering from advanced breast cancer.

As these combinations emerge as pivotal elements in oncology research, Akeso is proactive in expanding its portfolio of these next-generation therapies. The company has established itself as a frontrunner in the field of bispecific and multispecific antibodies for oncology, underlining its commitment to ushering in the next generation of cancer therapeutics.

Company Background

Founded in 2012, Akeso is a leading biopharmaceutical firm dedicated to designing, developing, and commercializing groundbreaking biological medicines. With a strong emphasis on innovation, Akeso leverages a suite of proprietary technologies across various platforms, providing a well-rounded ecosystem aimed at addressing critical medical needs in several disease areas.

As Akeso continues to push the boundaries of biopharmaceutical research, its focus on patient needs and commitment to ethical practices places it at the forefront of driving progress in cancer treatment. The ongoing studies and development pipelines signal a promising future for treating breast cancer and other serious health conditions worldwide, enhancing patient care and overall outcomes in oncology.